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Abstract
Background: Neuroleptic-induced movement disorders (NIMDs) have overlapping co-morbidity.
Earlier studies have described typical clinical movement patterns for individual NIMDs. This study
aimed to identify specific movement patterns for each individual NIMD using actometry.
Methods:  A naturalistic population of 99 schizophrenia inpatients using conventional
antipsychotics and clozapine was evaluated. Subjects with NIMDs were categorized using the
criteria for NIMD found in the Diagnostic and Statistical Manual for Mental Disorders – Fourth
Edition (DSM-IV).
Two blinded raters evaluated the actometric-controlled rest activity data for activity periods,
rhythmical activity, frequencies, and highest acceleration peaks. A simple subjective question was
formulated to test patient-based evaluation of NIMD.
Results: The patterns of neuroleptic-induced akathisia (NIA) and pseudoakathisia (PsA) were
identifiable in actometry with excellent inter-rater reliability. The answers to the subjective
question about troubles with movements distinguished NIA patients from other patients rather
well. Also actometry had rather good screening performances in distinguishing akathisia from other
NIMD. Actometry was not able to reliably detect patterns of neuroleptic-induced parkinsonism
and tardive dyskinesia.
Conclusion: The present study showed that pooled NIA and PsA patients had a different pattern
in lower limb descriptive actometry than other patients in a non-selected sample. Careful
questioning of patients is a useful method of diagnosing NIA in a clinical setting.
Background
Globally, many schizophrenia patients still suffer from
neuroleptic-induced movement disorders (NIMDs) [1-3]
in spite of the increasing use of second generation antip-
sychotics, which in general have a lower propensity for
NIMDs [4]. Although in earlier years movement adverse
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effects were even considered to be an indicator of antipsy-
chotic action [5], today they are seen as burdening and
stigmatizing phenomena that should be avoided by care-
ful choice of treatment [6]. NIMDs, which are investigated
in this study and classified in DSM-IV [7], include neu-
roleptic-induced akathisia (NIA), neuroleptic-induced
parkinsonism (NIP) and tardive dyskinesia (TD). Pseu-
doakathisia (PsA) is a movement disorder with objective
signs of akathisia, but without the subjective feeling of
restlessness [8]. PsA is not included in the DSM-IV classi-
fication [7].
Besides motor inconvenience, NIMD can cause subjective
suffering through cognitive or emotional disturbance [9].
Patients have described rigidity and dullness of thinking
in association with parkinsonism [10]. Akathisia causes
significant distress and is reported to be associated with
suicide attempts [11] and aggression [12]. It results in
reduced compliance with antipsychotic drug treatment
and thus a cause of psychotic relapses [13].
The interest in the instrumental measurement of NIMDs
in addition to clinical examination and observer-based
rating scales has long traditions. Instrumental measure-
ment has been reported 1) to identify more NIMDs
patients than observer-based ratings [14], 2) to be more
sensitive to sub-clinical motor changes [15], 3) to exhibit
greater linearity with regard to severity [15-17], and 4) to
need less training to achieve sufficient inter-rater reliabil-
ity and test-retest reliability [16].
Previous studies have mostly been conducted with
selected patients and non-NIMD controls, but in chronic
patients using long-term antipsychotics, different NIMD
often occur together [1-3].
Studies using instrumental measurement of neuroleptic- 
induced akathisia (NIA)
NIA has been studied by actometry (accelerometry or
actigraphy) [18-24] and by eletromyography (EMG) [25],
mostly in polysomnographic studies [26,27]. For exam-
ple, Gardos et al. [19] measured overall 24-hour motor
activity in 8 NIA patients by means of an actometer
strapped to the non-dominant ankle, and found that aka-
thisia had no relationship to nocturnal activity. Diurnal
motor activity analysis of wrist accelerometers worn by 16
NIA patients and by 16 non-NIA patients revealed that
NIA patients had higher levels of motor activity over a
two-day period [22]. Movement activity measured by
accelerometers on ankles and the waist in a standardized
rest activity (30 minutes) discriminated 10 pure NIA
patients from themselves while in remission and also
from 10 healthy controls with no overlap [21]. Actometry
was able to reveal akathisia in a patient who had mostly
subjective complaints and hypokinesia masked akathisia
[23]. The same method, however, did not discriminate 31
NIA patients from those without NIA in a clinical non-
selected sample of 99 patients with co-morbid NIMDs
[24]. The sensitivity of actometric measurement was 0.77
and specificity 0.57 at the optimal cut-off point, which
was 12000 of lower limb activity count [24].
Toe tremor was more informative than finger tremor in
distinguishing 6 akathisia patients from controls by
actometry. Characteristic of akathisia were low frequency
(less 4 Hz) rhythmic foot movements [18]. No differences
were found between NIA and pseudoakathisia (PsA) in
accelerometric recordings [20]. PsA prevalence in chronic
schizophrenia patients is 18% [28]. An EMG study using
a case definition for akathisia (i.e. 10 second duration and
less than 4 Hz in the anterior tibialis tracings) in the eval-
uation of 26 subjects (16 NIA patients) and yielded a sen-
sitivity of 69% and specificity of 70% in NIA detecting
[25].
Studies of neuroleptic-induced parkinsonism (NIP)
NIP has been studied by EMG [29,30] and force transduc-
ers [14,17,31], and NIP tremor has been studied by accel-
erometry [32-34]. NIP tremor occurred in the range of 5–
7 Hz when recorded from a pair of antagonist muscles in
EMG studies, and was distinguishable from the activity of
TD [29,30]. Mean tremor frequency measured by acceler-
ometry was over 5 Hz [33]. Accelerometric recordings
from 14 patients in frequencies between 4 and 7 Hz were
helpful in differentiating neuroleptic-induced tremor
from other NIMD and from psychogenic tremor [32].
Studies on tardive dyskinesia (TD)
TD has been studied instrumentally by EMG [29,30],
force transducers [14,16,17,31,35], and accelerometers
[35-37]. EMG studies described the movement pattern as
irregular bursts below 3 Hz, but almost all TD patients
had activity in limbs – 15 of 16 [29,30]. Instrumental
measurement has been used in TD to estimate current sta-
tus and treatment efficacy [35].
Qualitative actometry (analysing the frequency peak)
seemed highly specific in TD patients, with a mean Abnor-
mal Involuntary Movement Scale (AIMS) total score of
11.2 [37].
Aim of the study
Hyperkinetic movement disorders, like all neuropsychiat-
ric disorders [19], may non-specifically increase rest-activ-
ity, and therefore a qualitative analysis of movement
pattern may be the only way to use actometry for differen-
tiating diagnostic purposes in naturalistic samples. The
aim of our study was to analyze characteristic actometry
patterns of NIMDs and PsA in a naturalistic schizophrenia
population.BMC Neurology 2008, 8:10 http://www.biomedcentral.com/1471-2377/8/10
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Methods
We recruited 99 chronic schizophrenic institutionalized
adult patients from a state nursing home in Estonia [3].
Inclusion criteria were a DSM-IV diagnosis of schizophre-
nia or schizoaffective disorder, stable antipsychotic medi-
cation (for at least one month), and an age of 18–65 years.
Diagnosis was made using a semi-structured interview
according to DSM-IV criteria for schizophrenia by a psy-
chiatrist (SJ) and medical records. Patients with severe
somatic illness or neurological illness were excluded.
Written informed consent was obtained from the subjects
and the study was approved by the Ethics Review Com-
mittee on Human Research of the University of Tartu.
An experienced psychiatrist (SJ) assessed all subjects to
identify NIMDs (NIA, NIP, and NITD) in accordance with
DSM-IV criteria [7]. PsA diagnosis was established accord-
ing to Barnes and Braude [8]. NIMDs and PsA patients are
in this report defined as the movement disorders group.
The temporal connection between NIMD and PsA with a
neuroleptic medication was established retrospectively by
interview and medical records.
Seventy nine (79.8%) patients were receiving conven-
tional antipsychotics (mainly haloperidol, cyclopentixol,
perphenazine, levomepromazine, chlorpromazine, and
also thioridazine, sulpiride, chlorprotixen, fluphenazine),
while 20 (20.2%) were receiving clozapine (one of whom
used clozapine combined with sulpiride). No new atypi-
cal antipsychotics were used. The mean daily chlorpro-
mazine equivalent dose [38] was 328 mg (SD 221, range
1417).
The psychiatrist (SJ) asked one subjective question from
patients concerning their problems with movements: "Do
you have disturbing movement problems?" The answer
was allocated to one of four categories:
a) Not to my knowledge.
b) Yes, but it doesn't disturb me
c) Yes, and it disturbs me
d) Yes, and it is very difficult to cope with
The actometric recording was performed while sitting in a
standardized clinical interview for 30 minutes between 9
and 11 AM, a method described previously as measuring
"controlled rest activity" [21]. Controlled rest activity is a
parameter of motor activity in a situation where sitting
still is adequate and expected, but not instructed or
required. The actometers (PAM3, IM-systems, Baltimore,
USA) were attached to the ankles of the subjects to meas-
ure lower limb motor activity. Actometers are small com-
puterized movement detectors of match-box-size which
do not influence normal moving of the patient. The mode
of data collection was digital integration, and the sam-
pling rate was 40 Hz and the chosen epoch was 0.1s.
PAM3 records acceleration signals exceeding 0.1G. The
actometry and controlled rest activity method have been
described previously by Tuisku et al. [21] and Janno et al.
[24].
To test the feasibility and properties of actometric record-
ing in a normal clinical setting we trained raters without
previous experience of evaluating actometric recordings. A
team of five neuropsychiatrists developed rater instruc-
tions and a data collecting form. Data evaluation training
comprised two hours, followed by supervised evaluation
of ten actometric recordings. Two raters (BA and AV)
trained according to this procedure, and achieved an
appropriate level of inter-rater reliability (0.44 to 1.0,
mean 0.82) during their training phase. Raters were
blinded and had no access to patient data other than the
actometric recording.
The two raters evaluated all study subjects' actometric
activity recordings for the existence of activity periods, the
duration of activity periods (activity for at least 10 sec-
onds), the existence of rhythmical activity. Raters calcu-
lated from persistent rhythmical activities three most
dominant frequencies for every patient (if patients had
rhythmical activity with different frequencies). Raters
found the highest acceleration peaks in activity periods in
the scope of 10 seconds. After calculating inter-rater relia-
bility, a meeting between raters was held to establish con-
sensus values for the estimated frequencies of activity
periods for 27 patients. The extracted data was then
assessed by KT and SJ to find any patterns for individual
NIMDs and PsA. Answers to the subjective question were
analyzed for a correlation with movement disorders diag-
noses.
The inter-rater reliability was measured by kappa coeffi-
cients for categorical values and intra-class correlation
(ICC) coefficients for continuous values. A two-way
ANOVA mixed model was used to calculate ICC, so as to
estimate the reliability of a single rating [39]. One-way
ANOVA was performed to analyze the ability to discrimi-
nate different qualities of movement patterns. Differences
between the movement disorder (NIA, NIP, TD and PsA)
and the non-movement disorder groups in activity peri-
ods were analyzed by the Mann-Whitney two-tailed U-test
for continuous variables (frequency, amount of periods).
Chi-square analyze was used for dichotomous variables
(presence of activity periods, rhythmical activity). Where
necessary, Fisher's exact test was used for calculating sig-
nificance. The performances of movement patterns in caseBMC Neurology 2008, 8:10 http://www.biomedcentral.com/1471-2377/8/10
Page 4 of 8
(page number not for citation purposes)
identification were evaluated by receiver operating charac-
teristics (ROC) analyses. The software used in analyses
was SPSS 12.0 (SPSS Inc. Chicago, Illinois, USA).
Results
A total of 88 patients (89%) showed rhythmical activity
and their results were used in the analysis. Raters achieved
excellent inter-rater reliability in almost all parameters of
movement patterns of actometric recordings, except
defining the minimal frequency of movement patterns
(Table 1).
Movement disorders group patients had more activity
periods in actometric recordings than other patients
(Table 2). More than 95% of NIA and PsA patients
showed rhythmical activity. Patients who had movement
disorder and particularly NIP, PsA and NIA patients had
higher frequencies in rhythmical activity than other
patients (Table 3). NIMD and PsA, except TD, patients
had higher median acceleration peaks in rhythmical activ-
ity recordings than non-movement disorders group
patients (U = 0.575, p = 0.024).
The presence of rhythmical activity, amount of activity
periods, maximal frequency, and highest values of accel-
eration peaks differentiated between the subgroups of
NIMDs and PsA. The other parameters of movement pat-
terns showed no ability to discriminate between move-
ment disorders groups by one-way ANOVA analysis (data
not shown). Presence of activity periods and rhythmical
activity in actometric recordings had the best abilities to
discriminate the patient group of pooled NIA and PsA
(Table 2).
The PsA group differed mostly from the non-movement
disorders group in regard to median number of activity
periods and frequencies. The results of particular NIMD
groups and non-movement disorders group are presented
in Table 4.
The differences between particular movement disorder
and non-movement disorder groups in the highest accel-
eration peak medians are presented in Table 4. Highest
acceleration peak medians (i.e. greatest digital integration
of acceleration) in activity periods were almost signifi-
cantly (p = 0.053) different (Mann-Whitney U = 444)
between NIP (203, interquartile range (IQ) 89, 250) and
non-NIP (116, IQ 67, 190) groups. No significant differ-
ences were found between other groups.
Median values of third frequency and minimal frequency
were not statistically significantly different between
groups.
To evaluate screening properties of actometry against
DSM-IV and PsA diagnostic criteria we used ROC analysis.
The area under the ROC curve (AUC) of the lower limb
activity count was 0.80 for PsA and 0.84 for pooled aka-
thisia (NIA and PsA).
Answers to the subjective question differed between the
movement disorders and the non-movement disorder
group (Pearson chi-square 8.209, p = 0.004). The ROC
curve for the screening performance of the subjective
question in NIA is presented in Figure 1. ROC analysis of
the subjective question for differentiating abilities showed
an AUC value of 0.67 for NIMD and PsA, 0.87 for NIA,
0.52 for NIP, 0.46 for TD, and 0.25 for PsA.
Figure 1. Receiver Operating Characteristic (ROC) curves
for subjective question and lower limb activity count
against DSM-IV defined neuroleptic-induced akathisia
(NIA).
Discussion
Our main finding was that actometry could objectively
differentiate NIA and PsA patients from the non-move-
ment disorder group and from all the other NIMD
patients. Also, the subjective question on movement
problems was able to detect NIA patients from all other
subjects. Answers to this question were highly selective for
NIA cases, but not for other NIMDs and PsA.
The strength of the study is the naturalistic non-selected
patient sample. Therefore, we can generalize results to
other chronic schizophrenia in-patients. It is possible that
co-morbid movement disorders, existing in this real-life
sample, compromise the previously reported characteris-
tics of individual NIMDs or PsA. Therefore, a loss of dif-
ferentiating ability of actometry is seen in a clinical setting
like ours.
Table 1: Inter-rater reliability coefficients for actometry 
variables in 99 in-patients with schizophrenia: kappa for 
categorical and ICC coefficients for continuous measures.
kappa
presence of activity periods 0.905*
presence of rhythmical activity 0.786*
ICC (95% CI)
amount of activity periods 0.967 (0.951–0.978)*
dominant frequency 0.739 (0.624–0.822)*
second prevalent frequency 0.787 (0.672–0.864)*
third prevalent frequency 0.789 (0.672–0.867)*
minimal frequency 0.351 (0.149–0.525)#
maximal frequency 0.831 (0.750–0.887)*
highest value of acceleration peaks 0.841 (0.768–0.893)*
* p < 0.001
# p = 0.001BMC Neurology 2008, 8:10 http://www.biomedcentral.com/1471-2377/8/10
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A limitation of the study is that for practical reasons, the
clinical diagnosis of NIMD or PsA was made and the sub-
jective question was asked by the same clinician, which
could have contaminated the investigator's judgement.
Another limitation of our study was that it could not
detect the sub-clinical movement disorders, because we
used the DSM-IV [7] and PsA [8,20] diagnostic criteria as
the "gold standard": These criteria do not identify sub-
clinical cases. Thus, the non-movement disorder sub-
group may include sub-clinical movement disorder sub-
jects, who were not detectable by DSM-IV criteria for
NIMD. The latter is supported by the following findings:
1) even 75% of non-movement disorder subjects showed
rhythmical activity which can be related to movement dis-
orders, seldom a normal activity during rest; and 2) the
non-movement disorder patients had less activity periods
in recordings, but when they had, then frequencies were
quite similar to NIMD or PsA (mostly TD) subjects.
NIA and PsA
In this sample, we have previously shown that quantita-
tive actometry does not discriminate NIA patients from
those without NIA [24]. Our finding contrasted with the
finding of Tuisku et al. [21], who reported a good discrim-
ination by actometry of selected NIA patients and healthy
controls. It seems that the inclusion of PsA (which is a
hyperactive movement disorder and similar in actometric
recordings to NIA) in the non-NIA group, in accordance
with DSM-IV criteria, compromised the differentiating
ability of actometry in this population [24].
Table 2: Presence of activity periods and rhythmical activity in differentiating neuroleptic-induced movement disorders for 99 in-
patients with schizophrenia.
Presence of activity periods Presence of rhythmical activity
non-movement disorders vs.
NIMD and PsA
Pearson chi-square 5.547 2.726
p 0.035 0.099
NIA vs. non-NIA
Pearson chi-square 5.642 5.574
p 0.016 0.019
NIP vs. non-NIP
Pearson chi-square 0.113 4.505
p 0.714 0.034
TD vs. non-TD
Pearson chi-square 1.131 1.607
p 0.495 0.254
PsA vs. non PsA
Pearson chi-square 0.814 2.061
p 0.685 0.151
Pooled NIA and PsA vs. no akathisia
Pearson chi-square 8.491 11.027
p 0.004 0.001
Table 3: Neuroleptic-induced movement disorders patterns for 99 in-patients with schizophrenia.
Presence of 
activity periods 
n%
Median amount 
of activity 
periods IQ*
Presence of 
rhythmical 
activity n%
Median of 
dominant 
frequency Hz 
IQ*
Median of 
second 
frequency Hz 
IQ*
Median of third 
frequency Hz 
IQ*
Median of 
minimal 
frequency Hz 
IQ*
Median of 
maximal 
frequency Hz 
IQ*
Median highest 
value of 
acceleration 
peaks IQ*
non-movement 
disorders n = 32
25
78%
2
1.00–7.63
24
75%
0.50
0.40–0.59
0.43
0.40–0.61
0.55
0.48–0.78
0.33
0.30–0.45
0.65
0.50–0.98
106
57–193
NIA
n = 31
31
100%
13
5.00–22.00
30
97%
0.58
0.40–1.01
0.60
0.45–0.80
0.70
0.49–1.01
0.38
0.30–0.45
1.15
0.74–2.18
177
81–226
NIP
n = 23
20
87%
8
1.00–14.50
16
70%
0.75
0.50–0.95
0.73
0.51–4.11
0.93
0.60–1.09
0.40
0.35–0.49
1.05
0.65–2.26
216
140–250
TD
n = 32
30
94%
9.75
3.00–16.75
29
91%
0.55
0.40–0.80
0.55
0.45–0.93
0.65
0.46–0.95
0.40
0.30–0.45
0.95
0.63–2.03
125
75–206
PsA
n = 19
18
95%
16
10.50–25.50
18
95%
0.80
0.50–1.53
0.80
0.49–1.00
0.60
0.49–1.04
0.40
0.30–0.43
1.15
0.75–2.58
127
79–208
All patients
n = 99
88
89%
8
2.00–17.50
83
84%
0.55
0.40–0.80
0.55
0.40–0.80
0.65
0.50–0.98
0.35
0.30–0.45
0.90
0.60–1.45
129
80–213
* Interquartile rangeBMC Neurology 2008, 8:10 http://www.biomedcentral.com/1471-2377/8/10
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Our findings are consistent with a previous accelerometric
study [20], which found no differences between clinical
observations and accelerometric recordings of NIA and
PsA. We have previously reported that in NIA the area
under the ROC curve was 0.68 [24] for the actometric
activity count, and we now report that in PsA the discrim-
inatory power of actometry is better (ROC 0.80). The
overall activity count differentiated the pooled NIA and
PsA from other NIMD and non-movement disorder
patients.
Differences in median values of the actometric count for
the PsA group and non-movement disorder group vali-
dates the diagnosis of PsA. These patients have higher fre-
quency movements than other patients, but are not aware
of them (according to answers to our subjective question).
They have difficulties in noticing their disturbance, which
clearly distinguishes this disorder from NIA.
The subjective question was selective for NIA cases, but
not for other NIMDs or PsA. This is explained by the sub-
jective component of NIA. Asking such a subjective ques-
tion offers a cost-effective way of screening NIA with good
screening ability. Although the single question has its lim-
itations and is not enough to evaluate the various subjec-
tive discomforts associated with NIMD. Our results show
that even single question can be a useful method of diag-
nosing NIA in a clinical setting.
NIP
The parkinsonian tremor shows rhythmical activity in
accelerometric recordings, which discriminates NIP
patients from non-movement disorder patients. NIP
patients had higher peaks of accelerations in activity peri-
ods than other patients. Comparing the NIP group with
the non-movement disorder group made this finding
more significant. Parkinsonian hypokinesia, unlike other
NIMD or PsA, shows less movements (overall activity
Table 4: The differences in median values of actometric pattern qualities of particular neuroleptic induced movement disorders from 
non-movement disorder group for 99 in-patients with schizophrenia
amount of activity periods dominant frequency second frequency maximal frequency median maximum amplitude
NIA median 13 0.58 0.60 1.15 177
non-NIMD median 2 0.50 0.43 0.65 106
Mann-Whitney U 207 262 153 177 277
p <0.001 0.084 0.017 0.001 0.040
NIP median 8 0.75 0.73 1.05 216
non-NIMD median 2 0.50 0.43 0.65 106
Mann-Whitney U 282 127 58 143 145
p 0.140 0.040 0.009 0.106 0.023
TD median 9.75 0.55 0.55 0.95 127
non-NIMD median 2 0.50 0.43 0.65 106
Mann-Whitney U 294 267 163 209 305
p 0.003 0.145 0.030 0.013 0.110
PsA median 16 0.8 0.8 1.15 144
non-NIMD median 2 0.50 0.43 0.65 106
Mann-Whitney U 87 103 82 92 156
p < 0.001 0.004 0.011 0.002 0.042
NIA and PsA median 15.75 0.68 0.60 1.15 155
non-NIMD median 2 0.50 0.43 0.65 106
Mann-Whitney U 641 364 235 269 433
p 0.003 0.011 0.006 < 0.001 0.017
Receiver Operating Characteristic (ROC) curves for subjec- tive question and lower limb activity count against DSM-IV  defined neuroleptic-induced akathisia (NIA) Figure 1
Receiver Operating Characteristic (ROC) curves for 
subjective question and lower limb activity count 
against DSM-IV defined neuroleptic-induced aka-
thisia (NIA).BMC Neurology 2008, 8:10 http://www.biomedcentral.com/1471-2377/8/10
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count) in actometric recordings, which we have presented
previously [34]. In our study, the frequencies of rhythmic
activity in NIP were much lower (median below 1 Hz),
than reported by previous studies (above 4 Hz) [29,33].
One possible explanation is that by measuring lower limb
activity in a sitting position we could not detect the high
frequency NIP tremor, which in previous studies was
measured from upper limbs by actometry [33]. There may
have been a high frequency tremor (close to 10 Hz) in our
sample that we were not able to detect with our method
due to the limitation of the time window of our actome-
ters.
TD
TD usually affects only some body segments, mostly the
orofacial region and sometimes the legs. Recording of
ankle movements gave little information for detecting TD,
despite the fact that the movement pattern of TD has more
activity periods, rhythmical activity, and somewhat higher
frequencies than non-movement disorder patterns.
Conclusion
The actometric recording and analysing of the standard-
ized left-leg motor activity is moderately time-consuming,
but it may have limited use. The method can be used in
NIMD and PsA patients for differentiating akathisia
(pooled NIA and PsA) from other patients, but not for dis-
criminating between NIA and PsA. Our study employed
ankle recording only, and actometric recording from the
ankle and wrist simultaneously may give more informa-
tion for detecting NIMD in the schizophrenia patient pop-
ulation. Actometry allows a quantifiable recording of
current state of movement disorders and is thus useful in
research settings. Further research should focus on the
ability of actometry to show change in the patient condi-
tion. Initial studies in this direction have already been
done [21,35].
Actometry is useful for measuring change in the overall
movement count or patterns after a change of risk factors
(dosage, antipsychotic type, time course etc) in experi-
mental conditions, and further research can show the abil-
ity of actometric data to drive treatment decisions in a
clinical setting.
The present study showed that pooled NIA and PsA
patients had different patterns in lower limb descriptive
actometry than other patients in a non-selected sample.
Careful questioning of patients is a useful and clinically
significant method of diagnosing NIA in a clinical setting.
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